Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enolen (enzalutamide) implant in prostate cancer before radical prostatectomy
NCT06257693Phase 1Recruiting
- Sponsor
- Alessa Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzalutamide in prostate adenocarcinoma (3 cohorts), sponsored by Alessa Therapeutics. Primary endpoints: Adverse Events up to 12 months and Pharmacokinetics Profile up to 12 months. Started Jun 2024; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06257693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257693.